Cochrane Lab Reports on Harm Reduction in Heated Tobacco Products

Jul.30.2022
Cochrane Lab Reports on Harm Reduction in Heated Tobacco Products
New Cochrane lab research suggests that switching from traditional cigarettes to HTPs may lower the risk of certain illnesses.

The latest study on heated tobacco products has been released by the Cochrane laboratory. The report follows standard Cochrane screening and data extraction methods, and the majority of the data from the study suggests that harmful substance exposure associated with cancer, heart disease, and respiratory issues is lower with HTP compared to traditional cigarettes. This means that transitioning to HTP may decrease the risk of developing these diseases. However, the research team notes that due to the short duration of the studies, the data is not conclusive enough to fully determine these results.


Researchers emphasized that while they did not find any studies indicating whether HTP helps smokers quit, two Japanese research reports indicated that cigarette sales declined after the introduction of IQOS into the market.


In fact, during a recent online seminar with Kumamaru Hiroya, the Deputy Director of Kawasaki AOI General Hospital, it was stated that while nicotine replacement therapy (NRT), such as nicotine patches, has not produced the expected results, HTP has. Hiroya confirmed that since the local launch of heated tobacco products, the smoking rate has started to significantly decrease.


In short, after attempting nicotine replacement therapy guidance, it did not achieve significant success. However, since 2014, Japan has officially launched three types of heated tobacco products, which have penetrated 25% of the overall smoking population. So far, these products have successfully reduced Japan's smoking rate by 30% within three to four years," said Hiroya in a recent online seminar.


HTP's Aerosol Particles


In other studies, researchers from Kaunas University of Technology in Lithuania conducted an analysis in 2019 examining the levels of aerosol particles, carbonyls, and nicotine in the indoor air of HTPs (referred to as THS in the study). They compared the indoor concentrations of substances such as formaldehyde, acetaldehyde, benzene, toluene, nicotine, and particulate matter 2.5 in THS to the concentrations of traditional cigarettes and other known air pollutants.


According to data, compared to cigarette smoke and other pollutants, any adverse effects of thirdhand smoke (THS) on indoor air quality are negligible. "The use of THS results in several analytes, including nicotine, acetaldehyde, PM2.5 and PNC, being statistically significantly increased, but the levels obtained are much lower compared to those produced by conventional cigarettes (CC) under the same conditions (approximately 16 times, 8 times and 28 times lower for nicotine, acetaldehyde, PNC and PM2.5, respectively).


According to authors Violeta Kauneliene, Marija Meisutovic-Akhtarieva, and Dainius Martuzevicius, "In a controlled environment, the concentration of formaldehyde, toluene, and PM2.5 in THS (and vape) is much lower than in most other sources of pollution, such as traditional cigarettes and hookah.


Click to view the original research report.


Sorry, I cannot complete this task as there is no original text to translate. Please provide the original text to be translated.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.
May.08 by 2FIRSTS.ai
How AI Is Rewriting the Talent Playbook for the Nicotine Industry: JTI’s Case
How AI Is Rewriting the Talent Playbook for the Nicotine Industry: JTI’s Case
AI is moving from a back-office tool to a core organizational capability in the nicotine industry. Based on JTI’s responses, this 2Firsts feature examines how AI is reshaping talent strategy, internal mobility, decision-making and human accountability as global tobacco companies compete in the shift toward new nicotine categories.
Jun.17
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
InterTabac 2026: First conference program highlights now available online
InterTabac 2026: First conference program highlights now available online
With three months to go before the international tobacco and nicotine industry gathers again in Dortmund, InterTabac, together with NUBIZ and InterSupply, is set to bring around 800 exhibitors from across the globe to eleven exhibition halls. The three events will showcase innovation, market trends and industry networking, while the first conference program highlights are now online, offering trade visitors keynotes, panel discussions and masterclasses to support business decision-making.
Events
Jun.22
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Technology reported financial results on May 7, 2026, for the third quarter of fiscal 2026, covering the three months ended March 31, 2026. Revenue was $18.7 million, compared with $26.2 million in the third quarter of fiscal 2025 and $20.3 million in the prior quarter. Gross profit was $2.0 million, with gross margin of 10.7%. Net loss was $9.5 million, or $0.17 per share. The company said it held $18.0 million in cash as of March 31, 2026, up $468,000 sequentially.
May.08 by 2FIRSTS.ai
Trump’s Tobacco Investments and Industry Donations Draw Scrutiny as FDA Eases Vape and Nicotine Pouch Rules
Trump’s Tobacco Investments and Industry Donations Draw Scrutiny as FDA Eases Vape and Nicotine Pouch Rules
A report by KFF Health News says that as the Trump administration pursued a series of policies favorable to the nicotine and tobacco industry, President Donald Trump increased his holdings in tobacco companies while benefiting from substantial industry-linked political donations, prompting questions from public health advocates about potential conflicts of interest and regulatory direction.
Jun.12